Cleared Traditional

K243679 - MammoScreen® (4) (FDA 510(k) Clearance)

Jul 2025
Decision
216d
Days
Class 2
Risk

K243679 is an FDA 510(k) clearance for the MammoScreen® (4). This device is classified as a Radiological Computer Assisted Detection/diagnosis Software For Lesions Suspicious For Cancer (Class II - Special Controls, product code QDQ).

Submitted by Therapixel (Nice, FR). The FDA issued a Cleared decision on July 3, 2025, 216 days after receiving the submission on November 29, 2024.

This device falls under the Radiology FDA review panel. Regulated under 21 CFR 892.2090. A Radiological Computer Assisted Detection And Diagnostic Software For Suspected Lesions Is An Image Processing Device Intended To Aid In The Detection, Localization, And Characterization Of Lesions Suspicious For Cancer On Acquired Medical Images (e.g., Mammography , Mr, Ct, Ultrasound, Radiography). The Device Detects, Identifies And Characterizes Lesions Suspicious For Cancer Based On Features Or Information Extracted From The Images, And May Provide Information About The Presence, Location, And Characteristics Of The Lesion To The User. Primary Diagnostic And Patient Management Decisions Are Made By The Clinical User..

Submission Details

510(k) Number K243679 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 29, 2024
Decision Date July 03, 2025
Days to Decision 216 days
Submission Type Traditional
Review Panel Radiology (RA)
Summary Summary PDF

Device Classification

Product Code QDQ - Radiological Computer Assisted Detection/diagnosis Software For Lesions Suspicious For Cancer
Device Class Class II - Special Controls
CFR Regulation 21 CFR 892.2090
Definition A Radiological Computer Assisted Detection And Diagnostic Software For Suspected Lesions Is An Image Processing Device Intended To Aid In The Detection, Localization, And Characterization Of Lesions Suspicious For Cancer On Acquired Medical Images (e.g., Mammography , Mr, Ct, Ultrasound, Radiography). The Device Detects, Identifies And Characterizes Lesions Suspicious For Cancer Based On Features Or Information Extracted From The Images, And May Provide Information About The Presence, Location, And Characteristics Of The Lesion To The User. Primary Diagnostic And Patient Management Decisions Are Made By The Clinical User.

Similar Devices - QDQ Radiological Computer Assisted Detection/diagnosis Software For Lesions Suspicious For Cancer

Lunit INSIGHT DBT (V1.2)
K253796 · Lunit, Inc. · Mar 2026
Median LCS (internal name) / eyonis LCS (trade name) (1.0)
K251474 · Median Technologies · Feb 2026
Genius AI Detection 2.0
K243341 · Hologic, Inc. · Jul 2025
Prostate MR AI (VA10A)
K241770 · Siemens Healthcare GmbH · Mar 2025
Genius AI Detection 2.0 with CC-MLO Correlation
K230096 · Hologic, Inc. · May 2023
Genius AI Detection 2.0
K221449 · Hologic, Inc. · Oct 2022